English | Español

Novartis
+ Regulatory
Amanda Rupp | Aug 31, 2016

Sandoz's Erelzi gains FDA approval for multiple inflammatory diseases
+ Technology/Innovation
Jamie Barrand | Feb 20, 2016

Novartis' new AML therapy granted FDA Breakthrough Designation
+ Technology/Innovation
Jamie Barrand | Feb 20, 2016

Alcon, Transcend Medical partner on glaucoma therapy project
+ Technology/Innovation
Jamie Barrand | Feb 13, 2016

Sandoz acquires infliximab inhibitor treatment from Pfizer
+ Technology/Innovation
Kasey Schefflin- Emrich | Jan 28, 2016

FDA approves Cosentyx as treatment for two inflammatory conditions

Trending
+ Pharmaceuticals
Patient Daily | Aug 4, 2026

Merck reports mixed results for tulisokibart in recent clinical trials and financial update
+ Pharmaceuticals
Patient Daily | Aug 6, 2026

FDA approves Replimune’s melanoma drug Tudriqev after advisory committee debate
+ Regulatory
M. R. Armstrong | Aug 4, 2026

Public Policy Solutions on 340B: 'The program has enriched big hospital execs'
+ Pharmaceuticals
Patient Daily | Aug 5, 2026

Bristol Myers Squibb and AstraZeneca reportedly in merger talks amid industry changes